BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: Gastrointestinal Stromal Tumor (GIST) Market Spotlight

May 07, 2021

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, but still represent less than 1% of gastrointestinal (GI) tumors and only around 5% of sarcomas. Most GIST cases arise in the stomach, and the majority of the remaining cases begin in the small intestine, but they can begin anywhere in the GI tract, as well as in areas outside the GI tract such as the peritoneum and omentum. Metastasis occurs most commonly in the liver and omentum, and less commonly in the lungs. Bone and local lymph node metastases are rare.

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Gastrointestinal Stromal Tumor (GIST)
Back to the top Back to the top